ARTL
ARTELO BIOSCIENCES, INC.
Key Financials
Net Income
$-12879000
↓ 31.1%
EPS (Diluted)
$-12.52
↓ 310.5%
Operating Income
$-11404000
↓ 12.8%
Cash & Equivalents
$600000.00
↓ 91.3%
Total Liabilities
$4.1M
↑ 121.2%
Shareholders' Equity
$-1272000.00
↓ 144.5%
Total Assets
$2.8M
↓ 40.4%
Operating Cash Flow
$-8520000.00
↓ 2.0%
Recent SEC Filings
| Form Type | Filed Date | Link |
|---|---|---|
| 424B3 | 4/16/2026 | View on SEC |
| EFFECT | 4/15/2026 | View on SEC |
| S-1 | 4/7/2026 | View on SEC |
| 8-K | 4/7/2026 | View on SEC |
| D | 4/6/2026 | View on SEC |
| SCHEDULE 13G | 4/3/2026 | View on SEC |
| EFFECT | 3/30/2026 | View on SEC |
| 8-K | 3/30/2026 | View on SEC |
| D | 3/27/2026 | View on SEC |
| D | 3/27/2026 | View on SEC |
Company Information
| Field | Value |
|---|---|
| Ticker | ARTL |
| Company Name | ARTELO BIOSCIENCES, INC. |
| CIK | 1621221 |
| Sector | Pharmaceutical Preparations |
| Industry | Non-accelerated filer Smaller reporting company |
| Exchange | Nasdaq |
| SIC Code | 2834 |
| SIC Description | Pharmaceutical Preparations |
| Entity Type | operating |
| Fiscal Year End | 1231 |
| State of Incorporation | NV |
| Phone | 858-925-7049 |